{"DataElement":{"publicId":"4864237","version":"1","preferredName":"Disease Response Choi Criteria Category","preferredDefinition":"Patient categorization based on a composite set of criteria developed by Choi et al. using imaging techniques in the evaluation of gastrointestinal stromal tumors response to imatinib mesylate treatment.","longName":"RESP_CHOI_CRIT_CAT","context":"CCR","contextVersion":"1","DataElementConcept":{"publicId":"4864198","version":"1","preferredName":"Disease Response Choi Criteria Evaluation","preferredDefinition":"The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression._A composite set of criteria developed by Choi et al. using imaging techniques in the evaluation of gastrointestinal stromal tumors response to imatinib mesylate treatment. These criteria integrate changes in tumor size and tumor density._Systematic, objective appraisal of the significance, effectiveness, and impact of activities or condition according to specified objectives and criteria.","longName":"2607696v1.0:4864196v1.0","context":"CCR","contextVersion":"1","ObjectClass":{"publicId":"2607696","version":"1","preferredName":"Response","preferredDefinition":"In medicine, an improvement related to treatment.","longName":"C50995","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Disease Response","conceptCode":"C50995","definition":"The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2AF31F79-4CA1-08D3-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-03-05","endDate":null,"createdBy":"UMLLOADER_CTOM","dateCreated":"2007-03-05","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"4864196","version":"1","preferredName":"Choi Response Criteria in the Evaluation of Gastrointestinal Stromal Tumors Evaluation","preferredDefinition":"A composite set of criteria developed by Choi et al. using imaging techniques in the evaluation of gastrointestinal stromal tumors response to imatinib mesylate treatment. These criteria integrate changes in tumor size and tumor density.:Systematic, objective appraisal of the significance, effectiveness, and impact of activities or condition according to specified objectives and criteria.","longName":"C122394:C25214","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Choi Response Criteria in the Evaluation of Gastrointestinal Stromal Tumors","conceptCode":"C122394","definition":"A composite set of criteria developed by Choi et al. using imaging techniques in the evaluation of gastrointestinal stromal tumors response to imatinib mesylate treatment. These criteria integrate changes in tumor size and tumor density.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Evaluation","conceptCode":"C25214","definition":"Systematic, objective appraisal of the significance, effectiveness, and impact of activities or condition according to specified objectives and criteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1853980C-0D09-D362-E050-BB89AD43458F","latestVersionIndicator":"Yes","beginDate":"2015-06-12","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-06-12","modifiedBy":"ONEDATA","dateModified":"2015-06-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008563","version":"1","preferredName":"Therapy Results","preferredDefinition":"the results or effects (does not include CTC Adverse Events) of therapeutic agents or procedures administered to the patient.","longName":"TX_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B6690D31-4081-494A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-01-06","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2003-02-11","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1853980C-0D1A-D362-E050-BB89AD43458F","latestVersionIndicator":"Yes","beginDate":"2015-06-12","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-06-12","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"4864232","version":"1","preferredName":"Choi Response Criteria Category","preferredDefinition":"A composite set of criteria developed by Choi et al. using imaging techniques in the evaluation of gastrointestinal stromal tumors response to imatinib mesylate treatment. These criteria integrate changes in tumor size and tumor density._A grouping of items based on some commonality or by user defined characteristics.","longName":"CHOI_CRIT_CAT","context":"CCR","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"30","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Stable disease","valueDescription":"Stable disease","ValueMeaning":{"publicId":"4864234","version":"1","preferredName":"Stable disease","longName":"4864234","preferredDefinition":"Does not meet criteria for complete response, partial response or progressive disease.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1853980C-0D77-D362-E050-BB89AD43458F","latestVersionIndicator":"Yes","beginDate":"2015-06-12","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-06-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1853980C-0D90-D362-E050-BB89AD43458F","beginDate":"2015-06-12","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-06-12","modifiedBy":"ONEDATA","dateModified":"2015-06-12","deletedIndicator":"No"},{"value":"Partial response","valueDescription":"Partial response","ValueMeaning":{"publicId":"4864235","version":"1","preferredName":"Partial response","longName":"4864235","preferredDefinition":"> or = 10% decrease in the greatest maximal diameter or a > or = 15% decrease in tumor attenuation at CT or contrast enhancement at MRI imaging; no new lesions","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1853980C-0D9A-D362-E050-BB89AD43458F","latestVersionIndicator":"Yes","beginDate":"2015-06-12","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-06-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1853980C-0DB3-D362-E050-BB89AD43458F","beginDate":"2015-06-12","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-06-12","modifiedBy":"ONEDATA","dateModified":"2015-06-12","deletedIndicator":"No"},{"value":"Complete response","valueDescription":"Complete response","ValueMeaning":{"publicId":"4864236","version":"1","preferredName":"Complete response","longName":"4864236","preferredDefinition":"Disappearance of all lesions; no new lesions","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1853980C-0DBD-D362-E050-BB89AD43458F","latestVersionIndicator":"Yes","beginDate":"2015-06-12","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-06-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1853980C-0DD6-D362-E050-BB89AD43458F","beginDate":"2015-06-12","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-06-12","modifiedBy":"ONEDATA","dateModified":"2015-06-12","deletedIndicator":"No"},{"value":"Progressive disease","valueDescription":"Progressive disease","ValueMeaning":{"publicId":"4864233","version":"1","preferredName":"Progressive disease","longName":"4864233","preferredDefinition":"> or = 10% increase in the greatest maximal diameter and does not meet criteria for partial response by using tumor attenuation at CT or contrast enhancement at MR imaging or > or = 15% increase in tumor attenuation at CT or contrast enhancement at MR imaging and does not meet the criteria for partial response by using tumor size; new lesion; new intratumoral nodule or increase in the size of existing intratumoral nodule","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1853980C-0D54-D362-E050-BB89AD43458F","latestVersionIndicator":"Yes","beginDate":"2015-06-12","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-06-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1853980C-0E30-D362-E050-BB89AD43458F","beginDate":"2015-06-12","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-06-12","modifiedBy":"ONEDATA","dateModified":"2015-06-12","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008563","version":"1","preferredName":"Therapy Results","preferredDefinition":"the results or effects (does not include CTC Adverse Events) of therapeutic agents or procedures administered to the patient.","longName":"TX_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B6690D31-4081-494A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-01-06","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2003-02-11","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"4864231","version":"1","preferredName":"Choi Response Criteria in the Evaluation of Gastrointestinal Stromal Tumors Category","preferredDefinition":"A composite set of criteria developed by Choi et al. using imaging techniques in the evaluation of gastrointestinal stromal tumors response to imatinib mesylate treatment. These criteria integrate changes in tumor size and tumor density.:A grouping of items based on some commonality or by user defined characteristics.","longName":"C122394:C25372","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Choi Response Criteria in the Evaluation of Gastrointestinal Stromal Tumors","conceptCode":"C122394","definition":"A composite set of criteria developed by Choi et al. using imaging techniques in the evaluation of gastrointestinal stromal tumors response to imatinib mesylate treatment. These criteria integrate changes in tumor size and tumor density.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Category","conceptCode":"C25372","definition":"A grouping of items based on some commonality or by user defined characteristics.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1853980C-0D2E-D362-E050-BB89AD43458F","latestVersionIndicator":"Yes","beginDate":"2015-06-12","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-06-12","modifiedBy":"ONEDATA","dateModified":"2015-06-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"C3D:Central Cancer Clinical Database","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1853980C-0D3F-D362-E050-BB89AD43458F","latestVersionIndicator":"Yes","beginDate":"2015-06-12","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-06-12","modifiedBy":"REEVESD","dateModified":"2015-06-12","changeDescription":"Values are based on the Choi Criteria used in NCI CCR clinical trial.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008601","version":"1","longName":"C3D Domain","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811685","version":"1","longName":"CCR","context":"CCR"}]},{"publicId":"2182125","version":"1","longName":"CCR Implementation","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811673","version":"1","longName":"C3D","context":"CCR"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Response Assessment by Choi C","type":"Preferred Question Text","description":"Response Assessment by Choi Criteria","url":null,"context":"CCR"}],"origin":"C3D:Central Cancer Clinical Database","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1853980C-0DE0-D362-E050-BB89AD43458F","latestVersionIndicator":"Yes","beginDate":"2015-06-12","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-06-12","modifiedBy":"REEVESD","dateModified":"2015-06-12","changeDescription":"Curated to support NCI CCR clinical trial for locally advanced unresectable Chordoma.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}